CN105439961A - 奥拉帕尼的晶型i及其制备方法 - Google Patents
奥拉帕尼的晶型i及其制备方法 Download PDFInfo
- Publication number
- CN105439961A CN105439961A CN201510320070.XA CN201510320070A CN105439961A CN 105439961 A CN105439961 A CN 105439961A CN 201510320070 A CN201510320070 A CN 201510320070A CN 105439961 A CN105439961 A CN 105439961A
- Authority
- CN
- China
- Prior art keywords
- crystal formation
- preparation
- present
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(C=CC=*C1)=C1C(C)N=C Chemical compound CCC(C=CC=*C1)=C1C(C)N=C 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
2theta | d间隔 | 强度% |
6.42 | 13.77 | 37.75 |
6.85 | 12.91 | 12.20 |
8.31 | 10.64 | 5.94 |
10.41 | 8.50 | 4.95 |
12.68 | 6.98 | 100.00 |
12.91 | 6.86 | 17.03 |
13.29 | 6.66 | 6.06 |
13.74 | 6.45 | 5.39 |
15.06 | 5.88 | 58.69 |
15.86 | 5.59 | 7.48 |
16.73 | 5.30 | 5.69 |
17.67 | 5.02 | 7.54 |
18.65 | 4.76 | 4.83 |
19.17 | 4.63 | 8.24 |
19.76 | 4.49 | 13.29 |
20.19 | 4.40 | 11.20 |
21.01 | 4.23 | 10.88 |
21.56 | 4.12 | 4.04 |
22.15 | 4.01 | 33.47 |
22.65 | 3.93 | 2.82 |
23.03 | 3.86 | 2.93 |
24.26 | 3.67 | 3.90 |
26.25 | 3.39 | 4.17 |
29.05 | 3.07 | 5.77 |
30.41 | 2.94 | 1.81 |
31.30 | 2.86 | 1.56 |
32.44 | 2.76 | 2.36 |
33.80 | 2.65 | 0.66 |
35.54 | 2.53 | 1.17 |
36.84 | 2.44 | 0.90 |
2theta | d间隔 | 强度% |
3.39 | 26.07 | 5.24 |
4.33 | 20.40 | 5.87 |
6.43 | 13.76 | 49.29 |
6.78 | 13.05 | 13.68 |
10.42 | 8.49 | 17.05 |
12.69 | 6.98 | 97.29 |
13.36 | 6.63 | 10.10 |
15.06 | 5.88 | 82.14 |
16.75 | 5.29 | 7.93 |
17.69 | 5.01 | 22.77 |
19.09 | 4.65 | 15.34 |
19.77 | 4.49 | 8.59 |
20.23 | 4.39 | 5.38 |
21.01 | 4.23 | 42.18 |
22.17 | 4.01 | 100.00 |
23.28 | 3.82 | 17.38 |
26.13 | 3.41 | 8.88 |
29.07 | 3.07 | 14.50 |
30.56 | 2.93 | 5.26 |
33.41 | 2.68 | 5.82 |
34.43 | 2.60 | 6.39 |
38.63 | 2.33 | 2.29 |
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010211575.3A CN112010809A (zh) | 2015-06-12 | 2015-06-12 | 奥拉帕尼的晶型i及其制备方法 |
CN201510320070.XA CN105439961A (zh) | 2015-06-12 | 2015-06-12 | 奥拉帕尼的晶型i及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510320070.XA CN105439961A (zh) | 2015-06-12 | 2015-06-12 | 奥拉帕尼的晶型i及其制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010211575.3A Division CN112010809A (zh) | 2015-06-12 | 2015-06-12 | 奥拉帕尼的晶型i及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105439961A true CN105439961A (zh) | 2016-03-30 |
Family
ID=55550660
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010211575.3A Pending CN112010809A (zh) | 2015-06-12 | 2015-06-12 | 奥拉帕尼的晶型i及其制备方法 |
CN201510320070.XA Pending CN105439961A (zh) | 2015-06-12 | 2015-06-12 | 奥拉帕尼的晶型i及其制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010211575.3A Pending CN112010809A (zh) | 2015-06-12 | 2015-06-12 | 奥拉帕尼的晶型i及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN112010809A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017123156A1 (en) * | 2016-01-14 | 2017-07-20 | Scinopharm Taiwan, Ltd. | Crystalline forms of olaparib and manufacturing processes therefor |
US10662178B2 (en) | 2018-01-31 | 2020-05-26 | Apotex Inc. | Crystalline form of Olaparib |
US10703728B1 (en) | 2019-06-18 | 2020-07-07 | Scinopharm Taiwan, Ltd. | Crystalline form of olaparib and a process for preparing the same |
CN111689905A (zh) * | 2020-07-22 | 2020-09-22 | 天津理工大学 | 一种奥拉帕尼与马来酸的共晶及其制备方法 |
CN111995582A (zh) * | 2020-07-09 | 2020-11-27 | 天津理工大学 | 一种奥拉帕尼与尿素的共晶及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113264887B (zh) * | 2021-05-27 | 2022-03-25 | 神隆医药(常熟)有限公司 | 一种奥拉帕尼的新晶型x及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528714A (zh) * | 2006-10-17 | 2009-09-09 | 库多斯药物有限公司 | 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮的多晶型物 |
CN102238945A (zh) * | 2008-10-07 | 2011-11-09 | 阿斯利康(英国)有限公司 | 药物制剂514 |
-
2015
- 2015-06-12 CN CN202010211575.3A patent/CN112010809A/zh active Pending
- 2015-06-12 CN CN201510320070.XA patent/CN105439961A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528714A (zh) * | 2006-10-17 | 2009-09-09 | 库多斯药物有限公司 | 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮的多晶型物 |
CN102238945A (zh) * | 2008-10-07 | 2011-11-09 | 阿斯利康(英国)有限公司 | 药物制剂514 |
Non-Patent Citations (1)
Title |
---|
朱良漪 主编: "《分析仪器手册》", 31 May 1997, 化学工业出版社 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017123156A1 (en) * | 2016-01-14 | 2017-07-20 | Scinopharm Taiwan, Ltd. | Crystalline forms of olaparib and manufacturing processes therefor |
US10138211B2 (en) | 2016-01-14 | 2018-11-27 | Scinopharm Taiwan, Ltd. | Crystalline forms of olaparib and manufacturing processes therefor |
US10662178B2 (en) | 2018-01-31 | 2020-05-26 | Apotex Inc. | Crystalline form of Olaparib |
US10703728B1 (en) | 2019-06-18 | 2020-07-07 | Scinopharm Taiwan, Ltd. | Crystalline form of olaparib and a process for preparing the same |
CN111718300A (zh) * | 2019-06-18 | 2020-09-29 | 台湾神隆股份有限公司 | 奥拉帕尼新晶型和其制备方法 |
CN111995582A (zh) * | 2020-07-09 | 2020-11-27 | 天津理工大学 | 一种奥拉帕尼与尿素的共晶及其制备方法 |
CN111995582B (zh) * | 2020-07-09 | 2021-12-03 | 天津理工大学 | 一种奥拉帕尼与尿素的共晶及其制备方法 |
CN111689905A (zh) * | 2020-07-22 | 2020-09-22 | 天津理工大学 | 一种奥拉帕尼与马来酸的共晶及其制备方法 |
CN111689905B (zh) * | 2020-07-22 | 2021-12-03 | 天津理工大学 | 一种奥拉帕尼与马来酸的共晶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112010809A (zh) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105439961A (zh) | 奥拉帕尼的晶型i及其制备方法 | |
CN103694241A (zh) | Pci-32765的新晶型a及其制备方法 | |
CN107848979A (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
WO2016165650A1 (zh) | 奥拉帕尼与尿素的共晶及其制备方法 | |
CN106008515A (zh) | 依鲁替尼的新晶型及其制备方法 | |
JP6691218B2 (ja) | 選択的なs1p1受容体アゴニストの新規な結晶形及びその製造方法 | |
CN106432231A (zh) | Azd9291的药用盐、及其晶型和制备方法 | |
CN103788075A (zh) | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 | |
CN105801476A (zh) | 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用 | |
WO2022100395A1 (zh) | 一种巴洛沙韦酯晶型d及其制备方法 | |
CN110156793A (zh) | 瑞博西尼单琥珀酸盐新晶型及制备方法 | |
CN107721902A (zh) | 阿普斯特与烟酰胺的共结晶及其制备方法和应用 | |
CN104817536A (zh) | 适合药用的甲磺酸伊马替尼非针状α晶型及其制备方法 | |
Harriss et al. | Niclosamide methanol solvate and niclosamide hydrate: structure, solvent inclusion mode and implications for properties | |
CN108250138A (zh) | 阿帕替尼a晶型及其制备方法和应用 | |
CN107778295A (zh) | 迈瑞替尼化合物 | |
CN107663166A (zh) | 洛美他派及其制备方法和用途 | |
CN106699672B (zh) | 一种奥拉帕尼无定型物及其制备方法 | |
CN104974146A (zh) | 坎格列净的晶型e、晶型f及其制备方法 | |
CN108250137A (zh) | 阿帕替尼c晶型及其制备方法和应用 | |
CN106279325A (zh) | 一种依碳氯替泼诺新晶型及其制备方法 | |
CN104530024A (zh) | 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的晶型及其制备方法 | |
CN110156720A (zh) | 一种氢溴酸沃替西汀的微晶及其制备方法 | |
CN106478598A (zh) | 一种凡德他尼水合物晶体及其制备方法 | |
CN108250139A (zh) | 阿帕替尼b晶型及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 215123 B4-101, biological park, No. 218, Xing Hu Street, Suzhou Industrial Park, Suzhou, Jiangsu Applicant after: Suzhou crystal cloud medicine Polytron Technologies Inc Address before: 215123 B4-101, biological park, No. 218, Xing Hu Street, Suzhou Industrial Park, Suzhou, Jiangsu Applicant before: Crystal Pharmatech Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191115 Address after: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 No. 218 BioBAY B4-301 Applicant after: Suzhou best Pharmaceutical Co., Ltd. Address before: Suzhou City, Jiangsu Province, Suzhou City Industrial Park 215123 Xinghu Street No. 218 BioBAY B4-101 Applicant before: Suzhou crystal cloud medicine Polytron Technologies Inc |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160330 |